Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.47 |
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367599 | 0.84 | RECQL (0.51) | LMNAMEN1GAAKMT2ASLC40A1 | |
| SCHEMBL2406982 | 0.82 | HSD17B2 (0.44) | CLK1HSD17B2LMNANPSR1CA1 | |
| SCHEMBL2368002 | 0.81 | MEN1 (0.58) | CLK1LMNANPSR1MEN1GAA | |
| SCHEMBL2367251 | 0.80 | KEAP1 (0.54) | LMNANPSR1MEN1KMT2ASLC40A1 | |
| SCHEMBL26844377 | 0.80 | CRBN (0.56) | CLK1HSD17B2LMNANPSR1MEN1 | |
| SCHEMBL2367596 | 0.78 | CA1 (0.56) | LMNACA1CA2CRBN | |
| SCHEMBL2367468 | 0.78 | HTR6 (0.49) | LMNAMEN1KMT2ACA1CA2 | |
| SCHEMBL2367619 | 0.78 | ALDH1A1 (0.56) | LMNAGAASLC40A1CA1CA2 | |
| SCHEMBL2367180 | 0.78 | HSD17B2 (0.39) | HSD17B2LMNANPSR1GAACA1 | |
| SCHEMBL2367618 | 0.76 | KEAP1 (0.57) | LMNANPSR1GAAKMT2ASLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366687-B1 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | PURZER PHARMACEUTICAL CO LTD (CN) | 2015-11-04 | — | — | EP | disclosed |
| EP-2366687-B1 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | PURZER PHARMACEUTICAL CO LTD (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-8173693-B2 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2012-05-08 | — | — | US | disclosed |
| US-8173693-B2 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2012-05-08 | — | — | US | disclosed |
| US-8173693-B2 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2012-05-08 | — | — | US | disclosed |
| CN-102199148-A | Benzenesulfonamide derivatives and pharmaceutical compositions thereof | PURZER PHARMACEUTICAL CO LTD | 2011-09-28 | — | — | CN | disclosed |
| US-20110230651-A1 | Benzenesulfonamide derivatives and pharmaceutical composition therof | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2011-09-22 | — | — | US | disclosed |
| US-20110230651-A1 | Benzenesulfonamide derivatives and pharmaceutical composition therof | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2011-09-22 | — | — | US | disclosed |
| US-20110230651-A1 | Benzenesulfonamide derivatives and pharmaceutical composition therof | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2011-09-22 | — | — | US | disclosed |
| EP-2366687-A2 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | Purzer Pharmaceutical Co., Ltd. (CN) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366687-A2 | Benzenesulfonamide derivatives and pharmaceutical composition thereof | Purzer Pharmaceutical Co., Ltd. (CN) | 2011-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230651-A1 | Benzenesulfonamide derivatives and pharmaceutical composition therof | CCNI, CCNE1, CCND1 | CLK1 4251/4885HSD17B2 3109/4885LMNA 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.